NRG1 and cyclic hematopoiesis: Recently, a seminal investigation, utilizing the well-established and generally preferred rat model of CN lesions, has provided consistent experimental data, supporting the use of neuregulin-1β3 type II, i.e., glial growth factor 2 (GGF2), as a novel systemic treatment modality, with far superior dose-dependent neuroprotective and neurorestorative effects as compared to previous therapeutic counterparts analyzed [14].